Bleeding gastrointestinal
Abbott’s HUMIRA® (adalimumab) Receives Positive Opinion From European Medicines Agency For The Treatment Of Crohnâ?˛s … (Medical News Today)
Abbott announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA® (adalimumab) for the treatment of severe Crohnâ?˛s disease. HUMIRA will be the first self-administered biologic for the treatment of Crohn’s disease. [click link for full article]
